Algatech to launch microalgae-derived products from Euglena
08/08/2019
The move seeks to bring better quality ß-1,3-glucans-based products to market
08 Aug 2019 --- Microalgae-derived ingredients player Algatech has licensed the rights and intellectual property related to the production of β-1,3-glucan from Euglena Gracilis
Algatech has licensed the rights and intellectual property related to the production of β-1,3-glucan from US biotech F3 Platform Biologics.
Algatech intends to launch several products using the algae-derived beta glucan, which will expand Algatech’s existing product offering and support its mission to develop commercial, microalgae-based products.
Algatech Ltd. has licensed the rights and intellectual property of technology belonging to F3 Platform Biologics that is designed to extract β-1,3-glucans from Euglena gracilis microalgae.
Fermentation expert Dr. Brad Cox, who has been instrumental in developing F3’s cutting-edge capabilities, will lead the Euglena project at Algatech and support its fermentation activity.
Microalgae-derived ingredient specialists Algatech are to license the rights to the production of β-1,3-glucan from microalgae Euglena gracilis from US biotech firm F3 Platform Biologics.